International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
Prediction of response to Buruli ulcer treatment shortening with novel beta-lactam-containing antimicrobial combinations.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Villani Umberto, D'Agate Salvatore, Sáez-López Emma, Ramón-García Santiago, Pasqua Oscar Della
Аннотация
OBJECTIVES: Whilst rifampicin (RIF, q.d.) plus clarithromycin (CLA, b.i.d.) for 8 weeks is an effective treatment for Buruli ulcer (BU), this prolonged regimen presents challenges for adherence, particularly in community-based settings. Using a mechanism-based modelling and simulation framework, informed by In vitro bactericidal activity data, this study aimed to predict whether adding amoxicillin-clavulanate (AMX/CLV) could shorten BU treatment.
METHODS: In vitro time-kill data for RIF, CLA, and AMX/CLV, alone and in combination, against Mycobacterium ulcerans isolates were analysed using a nonlinear mixed-effects approach. Clinical trial simulations (n=70/arm) then assessed bacterial eradication times for standard therapy versus AMX/CLV-containing regimens, including higher RIF doses, while accounting for population pharmacokinetic variability and drug skin penetration.
RESULTS: In vitro time-kill analyses showed that, excluding isolate ITM070290, AMX/CLV-containing combinations provide comparable or superior potency and faster killing rates than the standard of care. Clinical trial simulations predicted these regimens can reliably achieve bacterial eradication within 4 and 6 weeks for moderate and high bacterial loads, respectively, with only one exception requiring over 8 weeks in high-burden scenarios.
CONCLUSIONS: Incorporating AMX/CLV alongside optimized RIF doses shows strong potential to shorten BU treatment from 8 weeks down to 4-6 weeks, supporting its ongoing evaluation in clinical trials.
METHODS: In vitro time-kill data for RIF, CLA, and AMX/CLV, alone and in combination, against Mycobacterium ulcerans isolates were analysed using a nonlinear mixed-effects approach. Clinical trial simulations (n=70/arm) then assessed bacterial eradication times for standard therapy versus AMX/CLV-containing regimens, including higher RIF doses, while accounting for population pharmacokinetic variability and drug skin penetration.
RESULTS: In vitro time-kill analyses showed that, excluding isolate ITM070290, AMX/CLV-containing combinations provide comparable or superior potency and faster killing rates than the standard of care. Clinical trial simulations predicted these regimens can reliably achieve bacterial eradication within 4 and 6 weeks for moderate and high bacterial loads, respectively, with only one exception requiring over 8 weeks in high-burden scenarios.
CONCLUSIONS: Incorporating AMX/CLV alongside optimized RIF doses shows strong potential to shorten BU treatment from 8 weeks down to 4-6 weeks, supporting its ongoing evaluation in clinical trials.